Clinical Research Directory
Browse clinical research sites, groups, and studies.
Memantine as an Additive Therapy in Patients With Traumatic Brain Injury
Sponsor: Mansoura University
Summary
Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron-specific enolase levels and improved Glasgow Coma Scale scores. However, other trials investigating memantine's impact on long-term cognitive function in TBI patients have yielded mixed results. There is a need for well-controlled studies to determine the efficacy of memantine in improving neurological and cognitive outcomes in patients with TBI.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-03-25
Completion Date
2025-11-30
Last Updated
2025-04-06
Healthy Volunteers
No
Interventions
Memantine
Memantine will be given either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital and then continued for 3 weeks. The memantine dose in the first 7 days is 30 mg twice daily, while during the remaining 3 weeks the dose is 10 mg twice daily
Mannitol
Mild to moderate TBI patients will receive mannitol in case of brain edema to reduce brain swelling and analgesic for headache such as; acetaminophen.
Locations (1)
Mansoura University
Al Mansurah, Dakahlia Governorate, Egypt